

Executive Corridor
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX
Switchboard Tel: 01325 38 0100
Foundation Trust Office: 01325 74 3625
Corporate Records Office: 01325 74 3700

Request for Information Reference: 07.21.33

FOI Direct line: 01325 743700
Email: cdda-tr.cddftfoi@nhs.net

Email only

16th August 2021

Freedom of Information Act 2000 – Request for Information

Thank you for submitting a request for information which we received on 16th July 2021 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to Oesophageal and Gastric Cancer and I am providing the following information in response to your specific questions:

1. Does your trust treat the following conditions?

- **Advanced oesophageal cancer**

The Trust does treat oesophageal cancer under the guidance of centre MDTs at Newcastle and South Tees Hospitals.

- **Advanced gastric cancer**

The Trust does treat oesophageal cancer under the guidance of centre MDTs at Newcastle and South Tees Hospitals.

- **In case you do not treat either of the above conditions, which other trust do you refer these patients to?**

Patients are referred to Newcastle Upon Tyne Hospitals Foundation Trust and South Tees Hospitals NHS Foundation Trust.

2. Please provide the total number of patients treated in the last 6 months for

- **Oesophageal cancer (any type)**

There were 15 patients treated in the last 6 months for Oesophageal cancer.

- **Oesophageal adenocarcinoma**

There were 7 patients treated in the last 6 months for Oesophageal adenocarcinoma.

- **Oesophageal squamous cell carcinoma**

There were 5 patients treated in the last 6 months for Oesophageal squamous cell carcinoma.

- **Unresectable oesophageal squamous cell carcinoma**

The Trust does not record this data.

- **Gastric cancer (any type)**

There were 8 patients treated in the last 6 months for Gastric cancer.

- **HER2 negative or HER2 untested gastric cancer**

There have been 15 gastric cases sent for HER2 testing Jan-Jun 2021:

3. For oesophageal squamous cell carcinoma only, how many patients were treated in the past 6 months with:

- **Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**

No patients were treated in the last 6 months with Platinum and Fluoropyrimidene based combination treatments.

- **Any other systemic anti-cancer therapy**

There was one patient that was treated with any other systemic anti-cancer therapy (EOX)

- **Palliative care only**

One patient was treated by Palliative care only for oesophageal squamous cell carcinoma only.

4. For gastric cancer only, how many patients were treated in the past 6 months with:

- **CapeOx (Capecitabine with Oxaliplatin)**

No patients were treated in the last 6 months with CapeOx

- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**

No patients were treated in the last 6 months with FOLFOX

- **Any other systemic anti-cancer therapy**

Sixteen patients were treated with other system anti-cancer therapy:

- ECX – 2
- EOX – 7
- FLOT – 1
- Herxuma – 1
- Herxuma + Capecitabine + Cisplatin – 3
- Paclitaxel – 2

- **Palliative care only**

Three patients were treated by palliative care only for gastric cancer only.

5. Does your trust participate in any ongoing clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part?

The Trust participates in Aspirin and SPIT clinical trials for the treatment of oesophageal cancer. One patient participated in the Aspirin trial and three patients participated in the SPIT trial.

6. Does your trust participate in any ongoing clinical trials for the treatment of gastric cancer? If so, can you please provide the name of each trial and the number of patients taking part?

The Trust does not participate in any clinical trials for gastric cancer.

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via cdda-tr.cddftfoi@nhs.

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; www.ico.gov.uk.

Yours sincerely

Corporate Records and Freedom of Information Facilitator